Health & FitScientific Study: This Marijuana Flavor Might Fight Pancreatic Cancer
Can people beat pancreatic cancer? What to know about Alex Trebek's update
Despite Alex Trebek's upbeat update, the overall statistics for surviving pancreatic cancer remain grim.
Often lost in thearound —and all the afflictions that the non-intoxicating cannabis compound can supposedly heal—are the legitimate scientific findings about cannabis’ palliative power, without which there would be no disingenuous oversells.
Here’s one: According to the findings of, stubborn and deadly pancreatic cancer might be treatable by a compound found in marijuana, but not a cannabinoid—a common plant chemical (phytonutrient), known for giving fruits and veggies their bright colors, which also contributes to the .
There are more common cancers, but few as deadly as this one
The pancreatic cancer diagnosis of "Jeopardy!" host Alex Trebek has focused the country's attention on the disease.
Researchers affiliated with the Dana-Farber Cancer Institute in Boston introduced two different types of pancreatic cancer cells, both isolated and introduced in lab mice, to a cannabis-derived drug.
The intellectual property of a Baltimore-based company called. (and also ), FBL-03G is “a cannabis-based pharmaceutical composition” derived , a metabolite of the “typical” cannabis sativa plant. Flavonoids are plant chemicals found in nearly all fruits and vegetables; flavonoids give flora their colors and are also associated with health benefits; thus, isolating and patenting a particular flavonoid could be a viable (and profitable) treatment.
NBC News' Tom Brokaw says politics, medical marijuana help distract from cancer: Report
SurvivorNet went to see the long time NBC News journalist to talk about his experience with cancer and how he’s learned to live with it in the years since his diagnosis.
Pancreatic cancer is particularly deadly, with a five-year survival rate of 8%. One reason why is that pancreatic cancer cells adapt to treatment and become resistant.
But when the pancreatic cancer encountered this particular cannabis-derived flavonoid—in concert with radiation—the cancer cells suffered “a major increase” in cell death. That is, the otherwise stubborn cancer cells suddenly were more likely to go away—to be cured—when exposed to both radiation and the flavonoid found in weed.
“The findings demonstrate the potential for this new cannabis derivative in the treatment of both localized and advanced pancreatic cancer,” the study’s authors wrote. “The results justify further studies to optimize therapy outcomes toward clinical translation.”
The findings were published online on July 23 in the journal Frontiers in Oncology.
To isolate FBL-03G, scientists used flash chromatography and then separated FBL-03G from other various flavonoids found in cannabis by how they interacted with other molecules. The flavonoids were delivered “directly” to the tumors via a method called “smart radiotherapy biomaterials,” described by one Harvard Medical School doctor as “.”
Justice Ruth Bader Ginsburg treated for pancreatic cancer
Justice Ruth Bader Ginsburg has been treated for pancreatic cancer in New York City, the Supreme Court announced Friday. © Allison Shelley/Getty Images WASHINGTON, DC - MARCH 18: U.S. Supreme Court Justice Ruth Bader Ginsburg speaks at an annual Women's History Month reception hosted by Pelosi in the U.S. capitol building on Capitol Hill in Washington, D.C. This year's event honored the women Justices of the U.S. Supreme Court: Associate Justices Ruth Bader Ginsburg, Sonia Sotomayor, and Elena Kagan.
In one specific experiment, mice left untreated died within 20 days; between 30% and 50% of mice treated with both the flavonoid and radiation therapy were still living after 40 days.
“Overall, the data demonstrates significant therapeutic potential for using FBL-03G in the treatment of both local and metastatic disease, significantly increasing survival,” the authors wrote.
The study is significant insofar as it identifies a cannabis compound that is not a cannabinoid that has therapeutic value.and are cannabinoids and interact with the human body’s endocannabinoid system, a network of receptors that regulate key functions like mood, appetite and sleep.
That’s relatively well known and is the scientific basis behind the(such as it is). But this study highlights something else entirely: Other compounds in cannabis—not having anything to do with the endocannabinoid system—may also have therapeutic value.
The study’s authors call, as most study authors do, for more research. It will require many more studies—including clinical trials involving humans—before the treatment described here can be patented and prescribed to humans with pancreatic cancer. And it’s also not at all clear if merely using cannabis in some way will deliver the same benefits, and if so, how. Juicing? Smoking? Oils? Who knows! But when you do see, remember why: there’s truth there. You just have to work hard to find it, and that work is still ongoing.
Here's Why Pancreatic Cancer Is Hard To Treat
Pancreatic cancer is one cancer type that is incredibly hard to treat, and now scientists know why.
Related Video: What You Need to Know About CBD Products (Provided by WLWT-TV Cincinnati)
Erytech flares after Phase IIb positive data with GRASPA
Erytech has good news to report in Phase IIb testing its GRASPA candidate in combination with chemotherapy for second-line treatment of metastatic pancreatic cancer. The study met its two main evaluation criteria. The 140-patient study evaluates eryaspase (GRASPA), L-asparaginase encapsulated in red blood cells, as a second-line treatment in combination with chemotherapy (gemcitabine or FOLFOX) for patients with metastatic cancer. The action flies 20% shortly after opening, at 17.30 euros.
Positive on the two main
criteria In many types of tumors, such as leukemias, lymphomas and pancreatic cancer, the level of asparagine synthetase (ASNS) is expected to play an important role in determining their sensitivity to treatment by asparaginase. The main objective of the study was to evaluate the effects of eryaspase on PFS or OS for patients with a low ASNS level, about 70% of the population in this study, with a predetermined goal of Hazard Ratio (HR) less than 0.85 for PFS or OS. This primary endpoint was achieved with a HR of 0.73 for PFS and 0.62 for OS. The effects of eryaspase have been demonstrated for all groups, regardless of the level of ASNS. For all patients, the randomized trial showed a HR of 0.57 for OS. Similar results were observed for PFS. The level of ASNS does not appear to be predictive, but seems to be a prognostic factor. The role of ASNS will be further analyzed in future clinical studies. Treatment with eryaspase was generally well tolerated. The complete data will be presented soon in a medical congress and will be the subject of a scientific publication.
"The preliminary results obtained with eryaspase in combination with standard therapy are very encouraging and show progress compared to gemcitabine or FOLFOX alone." The results of this study corroborate the potential of eryaspase as a therapeutic option in second-line treatment for patients with metastatic cancer, "commented Professor Pascal Hammel, principal investigator of this study. Erytech scheduled a conference call on March 28 to comment on the results of this clinical study.
For Bryan Garnier, the quality of the data observed might suggest that the range of possibilities is wider than expected for GRASPA. In the short term, he reiterates his opinion on the purchase and raises his goal from 30 to 35 euros. The analyst estimates that the probability of success in the relevant indication increases from 30 to 45%, that the peak penetration rate is adjusted from 10 to 15% and that the candidate could finally be adapted to patients regardless of their level. of ASNS. Jefferies confirms its opinion on the purchase and its valuation of 35 euros per share. The specialist also noted the good quality of the data and the effect regardless of the ASNS status of the patients. Paradoxically, it does not value GRASPA in this indication which is still very risky, but thinks that the laboratory could profit from the results to start negotiations with the FDA for an accelerated procedure, which would constitute a particularly favorable scenario.
Alex Trebek Releases New PSA to Raise Pancreatic Cancer Awareness: 'I Wished I Had Known Sooner' .
Alex Trebek Releases New PSA to Raise Pancreatic Cancer AwarenessFor the PSA, Trebek (who also made headlines this week when he called a fan with autism who wanted to wish him well) partnered with the World Pancreatic Cancer Coalition to announce the upcoming World Pancreatic Cancer Day, which will be Nov. 21. In the PSA, Trebek points out that cancer still only has an abysmal single-digit, five-year survival rate (2-9%) in most countries. He’s joined 80 organizations from 30 countries to raise awareness of the risks and symptoms.
[See This] Proof: Cannabis Oil Kills Cancer!! (through a microscope)
Cannabis Oil Kills Cancer!! (through a microscope) Artikel Terkait: - [Sejarah Ganja Illegal] Peneliti: Ganja Obat Mujarab Sejak Ribuan Tahun ...
Could cannabis oil cure cancer? BBC News
Subscribe to BBC News www.youtube.com/bbcnews The BBC's Alastair Leithead reports on how evidence is growing that cannabis could cure diseases like ...